Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.

Thumbnail
View / Open Files
Authors
  Bath, Philip M
Woodhouse, Lisa J
Appleton, Jason P
Beridze, Maia
Christensen, Hanne
  Dineen, Robert A
Duley, Lelia
Publication Date
2018-03
Journal Title
Lancet (London, England)
ISSN
0140-6736
Volume
391
Issue
10123
Pages
850-859
Language
eng
Type
Article
This Version
VoR
Physical Medium
Print-Electronic
Metadata
Show full item record
Citation
Bath, P. M., Woodhouse, L. J., Appleton, J. P., Beridze, M., Christensen, H., Dineen, R. A., Duley, L., et al. (2018). Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.. Lancet (London, England), 391 (10123), 850-859. https://doi.org/10.1016/s0140-6736(17)32849-0
Keywords
TARDIS Investigators, Humans, Brain Ischemia, Ischemic Attack, Transient, Ischemia, Acute Disease, Recurrence, Hemorrhage, Aspirin, Dipyridamole, Ticlopidine, Platelet Aggregation Inhibitors, Treatment Outcome, Drug Therapy, Combination, Thrombolytic Therapy, Risk Assessment, Prospective Studies, Research Design, Aged, Middle Aged, Georgia, Denmark, New Zealand, Female, Male, Stroke, United Kingdom, Clopidogrel
Sponsorship
Department of Health (via University of Nottingham) (109767)
Identifiers
External DOI: https://doi.org/10.1016/s0140-6736(17)32849-0
This record's URL: https://www.repository.cam.ac.uk/handle/1810/273812

Rights
Attribution 4.0 International
Licence URL: http://creativecommons.org/licenses/by/4.0/


The following licence files are associated with this item:

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International